{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T22:11:24Z","timestamp":1792793484042,"version":"4.5.0"},"reference-count":20,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,7]],"date-time":"2020-01-07T00:00:00Z","timestamp":1578355200000},"content-version":"vor","delay-in-days":616,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100007075","name":"ESMO","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007075","id-type":"DOI","asserted-by":"publisher"}]},{"name":"AstraZeneca"},{"name":"Bayer","id":[{"id":"https:\/\/ror.org\/04hmn8g73","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Merck Serono"},{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline plc","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Nippon Boehringer Ingelheim Co., Ltd."}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1093\/annonc\/mdy064","type":"journal-article","created":{"date-parts":[[2018,2,8]],"date-time":"2018-02-08T15:10:09Z","timestamp":1518102609000},"page":"1099-1107","source":"Crossref","is-referenced-by-count":34,"title":["The hard road to data interpretation: 3 or 6 months of adjuvant chemotherapy for patients with stage III colon cancer?"],"prefix":"10.1016","volume":"29","author":[{"given":"A.","family":"Sobrero","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Grothey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Iveson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Labianca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Yoshino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Taieb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Maughan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Buyse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Andr\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Meyerhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.F.","family":"Shields","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Souglakos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.-Y.","family":"Douillard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3806-3691","authenticated-orcid":false,"given":"A.","family":"Cervantes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl 6","key":"10.1093\/annonc\/mdy064_bb0010","doi-asserted-by":"crossref","first-page":"vi64","DOI":"10.1093\/annonc\/mdt354","article-title":"Early colon cancer: eSMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"24","author":"Labianca","year":"2013","journal-title":"Ann Oncol"},{"issue":"32","key":"10.1093\/annonc\/mdy064_bb0015","doi-asserted-by":"crossref","first-page":"3733","DOI":"10.1200\/JCO.2015.60.9107","article-title":"Capecitabine plus oxaliplatin compared with fluorouracil\/folinic acid as adjuvant therapy for stage III colon cancer: final results of the NO16968 randomized controlled phase III trial","volume":"33","author":"Schmoll","year":"2015","journal-title":"J Clin Oncol"},{"issue":"22","key":"10.1093\/annonc\/mdy064_bb0020","doi-asserted-by":"crossref","first-page":"5614","DOI":"10.1002\/cncr.27593","article-title":"Long-term neurotoxicity effects of oxaliplatin added to fluorouracil and leucovorin as adjuvant therapy for colon cancer: results from National Surgical Adjuvant Breast and Bowel Project trials C-07 and LTS-01","volume":"118","author":"Kidwell","year":"2012","journal-title":"Cancer"},{"issue":"21","key":"10.1093\/annonc\/mdy064_bb0025","doi-asserted-by":"crossref","first-page":"2699","DOI":"10.1200\/JCO.2013.49.1514","article-title":"Chemotherapy-induced neuropathy and its association with quality of life among 2- to 11-year colorectal cancer survivors: results from the population-based PROFILES registry","volume":"31","author":"Mols","year":"2013","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1093\/annonc\/mdy064_bb0030","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1159\/000094376","article-title":"Persistence of high-dose oxaliplatin-induced neuropathy at long-term follow-up","volume":"56","author":"Pietrangeli","year":"2006","journal-title":"Eur Neurol"},{"issue":"12","key":"10.1093\/annonc\/mdy064_bb0035","doi-asserted-by":"crossref","first-page":"3307","DOI":"10.1007\/s00520-013-1905-5","article-title":"Oxaliplatin-induced peripheral neuropathy\u2019s effects on health-related quality of life of colorectal cancer survivors","volume":"21","author":"Tofthagen","year":"2013","journal-title":"Support Care Cancer"},{"issue":"30","key":"10.1093\/annonc\/mdy064_bb0040","doi-asserted-by":"crossref","first-page":"3416","DOI":"10.1200\/JCO.2014.58.8533","article-title":"clinical course of oxaliplatin-induced neuropathy: results from the randomized phase III trial N08CB (Alliance)","volume":"33","author":"Pachman","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdy064_bb0045","volume":"35","author":"Shi","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdy064_bb0050","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdx783","volume":"28","author":"Grothey","year":"2017","journal-title":"Annals Oncol"},{"issue":"Suppl 5","key":"10.1093\/annonc\/mdy064_bb0055","article-title":"Updated results of the SCOT study: an international phase III randomised (1: 1) non-inferiority trial comparing 3 versus 6 months of oxaliplatin based adjuvant chemotherapy for colorectal cancer","volume":"28","author":"Iveson","year":"2017","journal-title":"Annals Oncol"},{"key":"10.1093\/annonc\/mdy064_bb0060","article-title":"FOLFOX4\/XELOX in stageII-III colon cancer: efficacy and safety results of the Italian Three or Six Colon Adjuvant (TOSCA) trial","volume":"28","author":"Labianca","year":"2017","journal-title":"Annals Oncol"},{"issue":"Suppl 5","key":"10.1093\/annonc\/mdy064_bb0065","article-title":"Three versus six months adjuvant oxaliplatin-based chemotherapy for patients with stage II colon cancer: per-protocol, subgroups and long-lasting neuropathy results","volume":"28","author":"Taieb","year":"2017","journal-title":"Annals Oncol"},{"issue":"Suppl 5","key":"10.1093\/annonc\/mdy064_bb0070","article-title":"Efficacy of 3 versus 6 months of oxaliplatin-based adjuvant chemotherapy for stage III colon cancer (CC): Results from phase III ACHIEVE trial as part of the International Duration Evaluation of Adjuvant therapy (IDEA) collaboration","volume":"28","author":"Yoshino","year":"2017","journal-title":"Annals Oncol"},{"issue":"2","key":"10.1093\/annonc\/mdy064_bb0075","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1111\/j.1525-1438.2007.00794.x","article-title":"Validation and reduction of FACT\/GOG-Ntx subscale for platinum\/paclitaxel-induced neurologic symptoms: a gynecologic oncology group study","volume":"17","author":"Huang","year":"2007","journal-title":"Int J Gynecol Cancer"},{"issue":"11","key":"10.1093\/annonc\/mdy064_bb0080","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1093\/annonc\/mdw404","article-title":"Phase III trial comparing 3-6 months of adjuvant FOLFOX4\/XELOX in stage II-III colon cancer: safety and compliance in the TOSCA trial","volume":"27","author":"Lonardi","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdy064_bb0085","doi-asserted-by":"crossref","first-page":"3732","DOI":"10.1200\/JCO.2007.12.2234","article-title":"Phase III study comparing a semimonthly with a monthly regimen of fluorouracil and leucovorin as adjuvant treatment for stage II and III colon cancer patients: final results of GERCOR C96.1","volume":"25","author":"Andre","year":"2007","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1093\/annonc\/mdy064_bb0090","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1093\/annonc\/mdi116","article-title":"A randomised comparison between 6 months of bolus fluorouracil\/leucovorin and 12 weeks of protracted venous infusion fluorouracil as adjuvant treatment in colorectal cancer","volume":"16","author":"Chau","year":"2005","journal-title":"Ann Oncol"},{"issue":"26","key":"10.1093\/annonc\/mdy064_bb0095","doi-asserted-by":"crossref","first-page":"2696","DOI":"10.1056\/NEJMoa043116","article-title":"Capecitabine as adjuvant treatment for stage III colon cancer","volume":"352","author":"Twelves","year":"2005","journal-title":"N Engl J Med"},{"issue":"Suppl 1","key":"10.1093\/annonc\/mdy064_bb0100","article-title":"Choice of randomisation time-point in non-inferiority studies of reduced treatment duration: experience from the SCOT study","volume":"12","author":"Paul","year":"2011","journal-title":"Trials"},{"key":"10.1093\/annonc\/mdy064_bb0105","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2007.25.18_suppl.4020","article-title":"How well do we communicate with our partients A survey of patients who received adjuvant therapy for colorectal cancer","author":"Love","year":"2007","journal-title":"Proceedings of the American Society of Clinical Oncology Gastrointestinal Cancers Symposium Orlando"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419345375?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419345375?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/29\/5\/1099\/31062356\/mdy064.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/29\/5\/1099\/31062356\/mdy064.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,26]],"date-time":"2021-06-26T04:39:58Z","timestamp":1624682398000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419345375"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5]]},"references-count":20,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,5]]}},"alternative-id":["S0923753419345375"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdy064","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2018,5]]}}}